

Eusebio Manchado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11123173/publications.pdf>

Version: 2024-02-01

19
papers

2,925
citations

516710

16
h-index

752698

20
g-index

20
all docs

20
docs citations

20
times ranked

6784
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100256.	1.1	4
2	Promoter-Driven Overexpression in <i>Chromobacterium vaccinii</i> Facilitates Access to FR900359 and Yields Novel Low Abundance Analogs. <i>Chemistry - A European Journal</i> , 2022, 28, .	3.3	6
3	SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1323-1334.	4.1	60
4	Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. <i>Cell Death and Differentiation</i> , 2018, 25, 828-840.	11.2	67
5	NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. <i>Science</i> , 2018, 362, 1416-1422.	12.6	267
6	USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. <i>Journal of Biological Chemistry</i> , 2017, 292, 4164-4175.	3.4	37
7	Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. <i>Nature Biotechnology</i> , 2017, 35, 577-582.	17.5	188
8	A Pipeline for Drug Target Identification and Validation. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 257-267.	1.1	16
9	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. <i>Cancer Immunology Research</i> , 2016, 4, 936-947.	3.4	132
10	A combinatorial strategy for treating KRAS-mutant lung cancer. <i>Nature</i> , 2016, 534, 647-651.	27.8	337
11	Conditional Reverse Tet-Transactivator Mouse Strains for the Efficient Induction of TRE-Regulated Transgenes in Mice. <i>PLoS ONE</i> , 2014, 9, e95236.	2.5	79
12	Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β^2 Signaling. <i>Cell</i> , 2014, 157, 382-394.	28.9	412
13	In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. <i>Nature</i> , 2014, 516, 423-427.	27.8	538
14	The APC/C cofactor Cdh1 prevents replicative stress and p53-dependent cell death in neural progenitors. <i>Nature Communications</i> , 2013, 4, 2880.	12.8	54
15	Non-mitotic functions of the Anaphase-Promoting Complex. <i>Seminars in Cell and Developmental Biology</i> , 2011, 22, 572-578.	5.0	71
16	Cdc14b regulates mammalian RNA polymerase II and represses cell cycle transcription. <i>Scientific Reports</i> , 2011, 1, 189.	3.3	35
17	The anaphase-promoting complex/cyclosome (APC/C): cell-cycle-dependent and -independent functions. <i>Biochemical Society Transactions</i> , 2010, 38, 65-71.	3.4	97
18	Targeting Mitotic Exit Leads to Tumor Regression In Vivo: Modulation by Cdk1, Mastl, and the PP2A/B55 Phosphatase. <i>Cancer Cell</i> , 2010, 18, 641-654.	16.8	188

#	ARTICLE	IF	CITATIONS
19	Genomic stability and tumour suppression by the APC/C cofactor Cdh1. <i>Nature Cell Biology</i> , 2008, 10, 802-811.	10.3	331